nach oben

Current Diabetes Reports

Erschienen in:

01.10.2019 | Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)

Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia

verfasst von: Colin P. Hawkes, Diva D. De Leon, Michael R. Rickels

Erschienen in: Current Diabetes Reports | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

New more stable formulations of glucagon have recently become available, and these provide an opportunity to expand the clinical roles of this hormone in the prevention and management of insulin-induced hypoglycemia. This is applicable in type 1 diabetes, hyperinsulinism, and alimentary hypoglycemia. The aim of this review is to describe these new formulations of glucagon and to provide an overview of current and future therapeutic opportunities that these may provide.

Recent Findings

Four main categories of glucagon formulation have been studied: intranasal glucagon, biochaperone glucagon, dasiglucagon, and non-aqueous soluble glucagon. All four have demonstrated similar glycemic responses to standard glucagon formulations when administered during hypoglycemia. In addition, potential roles of these formulations in the management of congenital hyperinsulinism, alimentary hypoglycemia, and exercise-induced hypoglycemia in type 1 diabetes have been described.

Summary

As our experience with newer glucagon preparations increases, the role of glucagon is likely to expand beyond the emergency use that this medication has been limited to in the past. The innovations described in this review likely represent early examples of a pending large repertoire of indications for stable glucagon.

Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777–81. https://doi.org/10.1172/JCI112884.CrossRefPubMedPubMedCentral

Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD clinical practice consensus guidelines 2018: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):178–92. https://doi.org/10.1111/pedi.12698.CrossRefPubMed

• Hawkes CP, Lado JJ, Givler S, De Leon DD. The effect of continuous intravenous glucagon on glucose requirements in infants with congenital hyperinsulinism. JIMD rep. 2019;45:45–50. https://doi.org/10.1007/8904_2018_140. This study demonstrates the effect of a continuous intravenous glucagon infusion on glucose requirement on infants with congenital hyperinsulinism.CrossRefPubMed

Salehi M, Vella A, McLaughlin T, Patti ME. Hypoglycemia after gastric bypass surgery: current concepts and controversies. J Clin Endocrinol Metab. 2018;103(8):2815–26. https://doi.org/10.1210/jc.2018-00528.CrossRefPubMedPubMedCentral

Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337–46. https://doi.org/10.2147/DMSO.S20633.CrossRefPubMedPubMedCentral

Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration – underevaluated and undertaught. Practical Diabetes Int. 2001;18(1):22–5. https://doi.org/10.1002/pdi.138.CrossRef

Rickels MR, Schutta MH, Mueller R, Kapoor S, Markmann JF, Naji A, et al. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab. 2007;92(3):873–9. https://doi.org/10.1210/jc.2006-2426.CrossRef

De Feo P, Perriello G, Torlone E, Ventura MM, Fanelli C, Santeusanio F, et al. Contribution of cortisol to glucose counterregulation in humans. Am J Phys. 1989;257(1 Pt 1):E35–42.

De Feo P, Perriello G, Torlone E, Ventura MM, Santeusanio F, Brunetti P, et al. Demonstration of a role for growth hormone in glucose counterregulation. Am J Phys. 1989;256(6 Pt 1):E835–43.

10.

Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–48. https://doi.org/10.1210/en.2011-1499.CrossRefPubMed

11.

Hawkes CP, Grimberg A, Dzata VE, De Leon DD. Adding glucagon-stimulated GH testing to the diagnostic fast increases the detection of GH-sufficient children. Horm Res Paediatr. 2016;85:265–72. https://doi.org/10.1159/000444678.CrossRefPubMedPubMedCentral

12.

Hawkes CP, Mavinkurve M, Fallon M, Grimberg A, Cody DC. Serial GH measurement after IV placement alone can detect levels above stimulation test thresholds in children. J Clin Endocrinol Metab. 2015:jc20153102. doi:https://doi.org/10.1210/jc.2015-3102.CrossRef

13.

Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010;59(11):2936–40. https://doi.org/10.2337/db10-0728.CrossRefPubMedPubMedCentral

14.

Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40(2):223–6.CrossRef

15.

Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91(3):819–28. https://doi.org/10.1172/JCI116302.CrossRefPubMedPubMedCentral

16.

Davis SN, Mann S, Galassetti P, Neill RA, Tate D, Ertl AC, et al. Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes. 2000;49(11):1897–903.CrossRef

17.

Rickels MR. Hypoglycemia associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Ann N Y Acad Sci. 2019. https://doi.org/10.1111/nyas.14214.CrossRef

18.

Hirsch IB, Marker JC, Smith LJ, Spina RJ, Parvin CA, Holloszy JO, et al. Insulin and glucagon in prevention of hypoglycemia during exercise in humans. Am J Phys. 1991;260(5 Pt 1):E695–704. https://doi.org/10.1152/ajpendo.1991.260.5.E695.CrossRef

19.

Mallad A, Hinshaw L, Schiavon M, Dalla Man C, Dadlani V, Basu R, et al. Exercise effects on postprandial glucose metabolism in type 1 diabetes: a triple-tracer approach. Am J Physiol Endocrinol Metab. 2015;308(12):E1106–15. https://doi.org/10.1152/ajpendo.00014.2015.CrossRefPubMedPubMedCentral

20.

Francescato MP, Stel G, Stenner E, Geat M. Prolonged exercise in type 1 diabetes: performance of a customizable algorithm to estimate the carbohydrate supplements to minimize glycemic imbalances. PLoS One. 2015;10(4):e0125220. https://doi.org/10.1371/journal.pone.0125220.CrossRefPubMedPubMedCentral

21.

Galassetti P, Tate D, Neill RA, Morrey S, Wasserman DH, Davis SN. Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes. 2003;52(7):1761–9.CrossRef

22.

Galassetti P, Tate D, Neill RA, Richardson A, Leu SY, Davis SN. Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab. 2006;290(6):E1109–17. https://doi.org/10.1152/ajpendo.00244.2005.CrossRefPubMed

23.

Sandoval DA, Guy DL, Richardson MA, Ertl AC, Davis SN. Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab. 2006;290(6):E1331–8. https://doi.org/10.1152/ajpendo.00283.2005.CrossRefPubMed

24.

Sandoval DA, Guy DL, Richardson MA, Ertl AC, Davis SN. Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes. 2004;53(7):1798–806.CrossRef

25.

Davey RJ, Howe W, Paramalingam N, Ferreira LD, Davis EA, Fournier PA, et al. The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes. J Clin Endocrinol Metab. 2013;98(7):2908–14. https://doi.org/10.1210/jc.2013-1169.CrossRefPubMed

26.

Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, et al. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005;147(4):528–34. https://doi.org/10.1016/j.jpeds.2005.04.065.CrossRefPubMed

27.

Adzick NS, De Leon DD, States LJ, Lord K, Bhatti TR, Becker SA, et al. Surgical treatment of congenital hyperinsulinism: results from 500 pancreatectomies in neonates and children. J Pediatr Surg. 2019;54(1):27–32. https://doi.org/10.1016/j.jpedsurg.2018.10.030.CrossRefPubMed

28.

Neylon OM, Moran MM, Pellicano A, Nightingale M, O'Connell MA. Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism. J Pediatr Endocrinol Metab. 2013;26(11–12):1157–61. https://doi.org/10.1515/jpem-2013-0115.CrossRefPubMed

29.

Mohnike K, Blankenstein O, Pfuetzner A, Potzsch S, Schober E, Steiner S, et al. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res. 2008;70(1):59–64. https://doi.org/10.1159/000129680.CrossRefPubMed

30.

Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of insulin for the diagnosis of Hyperinsulinemic hypoglycemia in infants and children. J Pediatr. 2016;168:212–9. https://doi.org/10.1016/j.jpeds.2015.09.045.CrossRefPubMed

31.

Hussain K, Bryan J, Christesen HT, Brusgaard K, Aguilar-Bryan L. Serum glucagon counterregulatory hormonal response to hypoglycemia is blunted in congenital hyperinsulinism. Diabetes. 2005;54(10):2946–51.CrossRef

32.

Kefurt R, Langer FB, Schindler K, Shakeri-Leidenmuhler S, Ludvik B, Prager G. Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. Surg Obes Relat Dis. 2015;11(3):564–9. https://doi.org/10.1016/j.soard.2014.11.003.CrossRefPubMed

33.

Goldfine AB, Patti ME. How common is hypoglycemia after gastric bypass? Obesity (Silver Spring). 2016;24(6):1210–1. https://doi.org/10.1002/oby.21520.CrossRef

34.

Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60(9):2308–14. https://doi.org/10.2337/db11-0203.CrossRefPubMedPubMedCentral

35.

Bradley D, Conte C, Mittendorfer B, Eagon JC, Varela JE, Fabbrini E, et al. Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest. 2012;122(12):4667–74. https://doi.org/10.1172/JCI64895.CrossRefPubMedPubMedCentral

36.

Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007;92(12):4678–85.CrossRef

37.

Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. 2014;146(3):669–80 e2. https://doi.org/10.1053/j.gastro.2013.11.044.CrossRefPubMed

38.

Salehi M, Gastaldelli A, D'Alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. J Clin Endocrinol Metab. 2014;99(6):2008–17. https://doi.org/10.1210/jc.2013-2686.CrossRefPubMedPubMedCentral

39.

Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249–54. https://doi.org/10.1056/NEJMoa043690.CrossRefPubMed

40.

Calabria AC, Gallagher PR, Simmons R, Blinman T, De Leon DD. Postoperative surveillance and detection of postprandial hypoglycemia after fundoplasty in children. J Pediatr. 2011;159(4):597–601 e1. https://doi.org/10.1016/j.jpeds.2011.03.049.CrossRefPubMedPubMedCentral

41.

Tharakan G, Behary P, Wewer Albrechtsen NJ, Chahal H, Kenkre J, Miras AD, et al. Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. Eur J Endocrinol. 2017;177(6):455–64. https://doi.org/10.1530/EJE-17-0446.CrossRefPubMedPubMedCentral

42.

Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon-release inhibitor. J Clin Invest. 1984;74(6):2296–9.CrossRef

43.

Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia. 1998;41(10):1180–6.CrossRef

44.

Rickels MR, Naji A. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients. Diabetes Obes Metab. 2010;12(8):731–3. https://doi.org/10.1111/j.1463-1326.2010.01208.x.CrossRef

45.

Abrahamsson N, Borjesson JL, Sundbom M, Wiklund U, Karlsson FA, Eriksson JW. Gastric bypass reduces symptoms and hormonal responses in hypoglycemia. Diabetes. 2016;65(9):2667–75. https://doi.org/10.2337/db16-0341.CrossRefPubMed

46.

Steiner SS, Li M, Hauser R, Pohl R. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol. 2010;4(6):1332–7. https://doi.org/10.1177/193229681000400606.CrossRefPubMedPubMedCentral

47.

Food and Drug Administration. GlucaGen. NDA 20–918/S-012. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20918s012lbl.pdf. Accessed 03/09/2019.

48.

Food and Drug Administration. Glucagon for Injection. NDA 20–928. 1999. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20928.pdf. Accessed 03/09/2019.

49.

Ghodke S, Nielsen SB, Christiansen G, Hjuler HA, Flink J, Otzen D. Mapping out the multistage fibrillation of glucagon. FEBS J. 2012;279(5):752–65. https://doi.org/10.1111/j.1742-4658.2011.08465.x.CrossRefPubMed

50.

Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010;4(6):1357–67. https://doi.org/10.1177/193229681000400609.CrossRefPubMedPubMedCentral

51.

Taleb N, Haidar A, Messier V, Gingras V, Legault L, Rabasa-Lhoret R. Glucagon in artificial pancreas systems: potential benefits and safety profile of future chronic use. Diabetes Obes Metab. 2017;19(1):13–23. https://doi.org/10.1111/dom.12789.CrossRefPubMed

52.

Hovelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531–7. https://doi.org/10.2337/dc17-1402.CrossRefPubMed

53.

Glezer S, Hovelmann U, Teng S, Lamers D, Odoul M, Correia J, et al. BioChaperone glucagon (BCG), a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia. Diabetes. 2018;67(Supplement 1):305–OR. https://doi.org/10.2337/db18-305-OR.CrossRef

54.

Castle JR, Youssef JE, Branigan D, Newswanger B, Strange P, Cummins M, et al. Comparative pharmacokinetic/pharmacodynamic study of liquid stable glucagon versus lyophilized glucagon in type 1 diabetes subjects. J Diabetes Sci Technol. 2016;10(5):1101–7. https://doi.org/10.1177/1932296816653141.CrossRefPubMedPubMedCentral

55.

Haymond MW, DuBose SN, Rickels MR, Wolpert H, Shah VN, Sherr JL, et al. Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes. J Clin Endocrinol Metab. 2017;102(8):2994–3001. https://doi.org/10.1210/jc.2017-00591.CrossRefPubMed

56.

• Rickels MR, Ruedy KJ, Foster NC, Piche CA, Dulude H, Sherr JL, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264–70. https://doi.org/10.2337/dc15-1498. In this study, the authors demonstrate the comparable efficacy of intranasal glucagon with standard intramuscular glucagon in managing hypoglycemia in patients with type 1 diabetes.CrossRefPubMed

57.

Meiffren G, Teng S, Ranson A, Gaudier M, Duracher D, Soula R et al. Preclinical efficacy of a stable aqueous formulation of human glucagon with BioChaperone Technology (BC GLU). American Diabetes Association 77th Scientific Sessions; San Diego, CA 2017. p. 1150-P.

58.

Wilson LM, Castle JR. Stable liquid glucagon: beyond emergency hypoglycemia rescue. J Diabetes Sci Technol. 2018;12(4):847–53. https://doi.org/10.1177/1932296818757795.CrossRefPubMedPubMedCentral

59.

Ranson A, Hövelmann U, Seroussi C, Lamers D, Correia J, Zijlstra E et al. Biochaperone glucagon, a stable ready-to-use liquid glucagon formulation enabled by biochaperone technology, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia. Advanced Technologies & Treatment for Diabetes; 20–23 February 2019; Berlin, Germany 2019.

60.

A trial to investigate the safety and the pharmacokinetic, pharmacodynamic characteristics of two BioChaperone® glucagon formulations compared to marketed GlucaGen® in Subjects With T1DM. https://ClinicalTrials.gov/show/NCT03176524.

61.

Newswanger B, Ammons S, Phadnis N, Ward WK, Castle J, Campbell RW, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol. 2015;9(1):24–33. https://doi.org/10.1177/1932296814565131.CrossRefPubMedPubMedCentral

62.

Cersosimo E, Cummins MJ, Kinzell JH, Michalek J, Newswanger BJ, Prestrelski SJ, et al. A phase 2 comparative safety PK/PD study of stable nonaqueous glucagon (g-Pen) vs. Lilly glucagon for treatment of severe hypoglycemia. Diabetes Care. 2014;63(Supplement 1A):LB1.

63.

Pontiroli AE. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia. J Diabetes Sci Technol. 2015;9(1):38–43. https://doi.org/10.1177/1932296814557518.CrossRefPubMed

64.

Locemia Solutions ULC. Safety and efficacy of a novel glucagon formulation in type 1 diabetic patients following insulin-induced hypoglycemia (AMG102). https://clinicaltrials.gov/ct2/show/results/NCT01556594. Accessed 03/13/19 2019.

65.

Food and Drug Administration. BAQSIMI (glucagon) nasal powder. NDA 210134. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf. Accessed 30 Aug 2019.

66.

Palylyk-Colwell E, Ford C. A transdermal glucagon patch for severe hypoglycemia. CADTH Issues in Emerging Health Technologies. Ottawa (ON)2016. p. 1–7.

67.

Safety and efficacy of ZP-glucagon to injectable glucagon for hypoglycemia. https://ClinicalTrials.gov/show/NCT02459938.

68.

Hompesch M, Grosjean P, Morrow L, Hijazi Y, Ishibai M, Teichert L et al. 1066-P / 1066 - The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic, and pharmacodynamic data from a study in healthy volunteers. American Diabetes Association 77th Scientific Sessions; 2017; San Diego 2017.

69.

Sanofi Announces Q2 2016 Results. http://www.news.sanofi.us/2016-07-29-Sanofi-Announces-Q2-2016-Results.

70.

Uribe-Bruce L, Morrow L, Canney L, Pichotta P, Hompesch M, Krasner A et al. Pharmacokinetic (Pk) and pharmacodynamic (PD) profiles of BiOD-961 compared with marketed glucagons. American Diabetes Association 2015.

71.

• Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24(4):643–5. This seminal study established the mini-dose glucagon approach to managing impending hypoglycemia in pediatric patients with type 1 diabetes.CrossRef

72.

Haymond MW, Redondo MJ, McKay S, Cummins MJ, Newswanger B, Kinzell J, et al. Nonaqueous, mini-dose glucagon for treatment of mild hypoglycemia in adults with type 1 diabetes: a dose-seeking study. Diabetes Care. 2016;39(3):465–8. https://doi.org/10.2337/dc15-2124.CrossRefPubMedPubMedCentral

73.

• Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, et al. Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care. 2018;41(9):1909–16. https://doi.org/10.2337/dc18-0051. This is the first study to demonstrate effective prevention of exercise-induced hypogylcemia with mini-dose glucagon when compared to insulin reduction and glucose ingestion in individuals with type 1 diabetes.CrossRefPubMedPubMedCentral

74.

Hovelmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes Obes Metab. 2019;21(3):601–10. https://doi.org/10.1111/dom.13562.CrossRefPubMed

75.

Steineck IIK, Ranjan A, Schmidt S, Clausen TR, Holst JJ, Norgaard K. Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. Diabetologia. 2019;62(4):582–92. https://doi.org/10.1007/s00125-018-4807-8.CrossRefPubMed

76.

Yale JF, Dulude H, Egeth M, Piche CA, Lafontaine M, Carballo D, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423–32. https://doi.org/10.1089/dia.2016.0460.CrossRefPubMedPubMedCentral

77.

Sherr JL, Ruedy KJ, Foster NC, Piche CA, Dulude H, Rickels MR, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555–62. https://doi.org/10.2337/dc15-1606.CrossRefPubMedPubMedCentral

78.

Haidar A, Rabasa-Lhoret R, Legault L, Lovblom LE, Rakheja R, Messier V, et al. Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes. J Clin Endocrinol Metab. 2016;101(1):214–23. https://doi.org/10.1210/jc.2015-3003.CrossRefPubMed

79.

The bihormonal ilet bionic pancreas feasibility study. https://ClinicalTrials.gov/show/NCT03840278.

80.

Glucagon infusion in T1D patients with recurrent severe hypoglycemia: effects on counterregulatory responses. https://clinicaltrials.gov/ct2/show/NCT03490942.

81.

Thornton P, Truong L, Reynolds C, Rodriguez L, Cummins M, Junaidi K. Continuous infusion of subcutaneous ready-to-use stable liquid glucagon has similar efficacy to intravenous reconstituted glucagon in children with congenital hyperinsulinism. Pediatric Academic Society; Baltimore, MD 2019.

82.

Open-label trial evaluating efficacy and safety of dasiglucagon in children with congenital hyperinsulinism. https://ClinicalTrials.gov/show/NCT03777176.

83.

CSI-glucagon for prevention of hypoglycemia in children with congenital hyperinsulinism. https://ClinicalTrials.gov/show/NCT02937558.

84.

Laguna Sanz AJ, Mulla CM, Fowler KM, Cloutier E, Goldfine AB, Newswanger B, et al. Design and clinical evaluation of a novel low-glucose prediction algorithm with mini-dose stable glucagon delivery in post-bariatric hypoglycemia. Diabetes Technol Ther. 2018;20(2):127–39. https://doi.org/10.1089/dia.2017.0298.CrossRefPubMedPubMedCentral

Titel: Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia
verfasst von: Colin P. Hawkes
Diva D. De Leon
Michael R. Rickels
Publikationsdatum: 01.10.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 10/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1216-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D

Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy

Regulation of Hepatic Metabolism, Recent Advances, and Future Perspectives

Emerging Insights and Interventions for Diabetic Retinopathy

Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy

Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges